Autoimmunity

Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences

Retrieved on: 
Monday, March 20, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, WCN, Congress, Autoimmunity, Simulation, ALPN, Society, Treatment, International Society, Inflammation, Pharmaceutical industry, Safety, Nephrology, Pharmacokinetics

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).
  • Poster Title: Early Clinical PK/PD Modeling and Simulation of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, to Support Clinical Trials in Multiple Autoantibody-and/or B Cell-Related Diseases
    Poster Title: Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, & Pharmacodynamics of Povetacicept (ALPN-303), a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inflammation, Week, The New England Journal of Medicine, Autoimmunity, American Academy, Depigmentation, Patient, AAD, BID, American Academy of Dermatology, Vitiligo, LTE, Skin, Safety, Pharmaceutical industry

The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.

Key Points: 
  • The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.
  • “The results presented today at AAD are significant because they provide important long-term efficacy and safety data for nonsegmental vitiligo patients treated with Opzelura,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Approximately 29% of patients randomized to the withdrawal arm (i.e., applying vehicle cream) relapsed (
  • “Vitiligo is a chronic condition and these results demonstrate the long-term potential of this medical treatment for people with vitiligo who are interested in repigmentation.”

Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insights Report 2023-2028: One of the Most Studied Immune Checkpoint After PD-1 and CTLA-4 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 17, 2023
Health, Other Health, Patent, Human, Diabetes, NOD, MHC, Cancer, NK, Research, Infection, Mercury, Cell, Autoimmunity, FGL1, Autoimmune disease, Immune system, Knowledge, Growth, PD-1, B cell, Metastasis, Pharmaceutical industry, Vaccine, LAG-3

The "Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • LAG-3 is an immune checkpoint and has been considered as a target for developing drugs and therapies for the treatment of cancer, chronic infectious diseases, and autoimmune diseases.
  • Future research also needs to focus on the effects of LAG-3 inhibition on other cells apart from the conventional T cells.
  • Number Of LAG-3 Inhibitor Drugs In the Market: 1 Drug
    Approved LAG-3 Inhibitor Drug Dosage, Patent & Pricing Insight
    Number Of LAG-3 Inhibitor Drugs In Clinical Trials: > 35 Drugs
    LAG-3 Inhibitor Drugs Clinical Trials Insight By Company, Country, Indication, & Phase

Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, American Academy of Dermatology, American Academy, Doctor of Philosophy, Development, MD, AAD, ALPN, HV, Treatment, Autoimmunity, Inflammation, Vaccine, Safety, Pharmacokinetics, Research

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of povetacicept, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of povetacicept, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.
  • Poster Title: Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases (RUBY-1)
    Presenter: Stanford Peng, MD, PhD, President and Head of Research and Development, Alpine Immune Sciences

Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit

Retrieved on: 
Thursday, March 16, 2023
Annual report, Cancer, Research, Autoimmunity, Psychiatry, Neurology, Failure, DSM-IV codes, MDD, Breakthrough therapy, Prader–Willi syndrome, CD40L, Government, Long COVID, COVID-19, Pain, FDA, Central nervous system, Infection, Hydrogen chloride, Security (finance), CNS, Fibromyalgia, Smallpox, Orphan drug, SL, Disease, Risk, Therapy, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.

Key Points: 
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is currently enrolling with interim data expected in the fourth quarter of 2023.
  • Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, March 16, 2023
Gene editing, BCMA, Research and development, IND World's Fair Line, Stem cell, Development, Culture, Cancer, Bangladesh Technical Education Board, CD47, Epithelium, ADA, Hepatocyte, State Administrative Expenses, CAR, ISSCR, CD19, Cell, Success, Immune system, Diabetes, Research, CD22, AACR, Lymphoid leukemia, NIH, Patient, ASH, Safety, Letter, Contingency, Retinal pigment epithelium, Serum, Survival, SANA, Autoimmunity, Administration, Immunosuppression, Fusome, Investment, GAAP, Disease, Biotechnology, IND, Mobile phone, Pharmaceutical industry, Vaccine, Cryptocurrency, Beam

SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
  • Sana expects an investigator sponsor trial using primary human hypoimmune-modified islet cells transplanted in type 1 diabetes patients to begin later this year.
  • In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023
Lead, Finance, Public expenditure, SCLC, Chemistry, Food and Drug Administration, Horizon, NSCLC, GSPT1, Trial of the century, Lung cancer, PK, Fast Track, MGD, Cytokine, B-cell lymphoma, MTD, American Association for Cancer Research, Index, MYC, Research, AACR, Therapy, PD, Jennifer, Patient, Inflammation, FDA, VAV1, Cancer, Safety, Carcinoma, R, CDK2, Autoimmunity, Drug discovery, DLBCL, Treatment of lung cancer, Drug development, EORTC, Priority review, Process, Administration, Senior, Queen, Accelerated approval (FDA), Food, Research and development, Cryptocurrency, Pharmaceutical industry, G&A, IND

Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.

Key Points: 
  • Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.
  • When activated, VAV1 relays a signal cascade that results in immune cell activation and the secretion of several pro-inflammatory cytokines.
  • Net Loss: Net loss for the fourth quarter of 2022 was $30.8 million compared to $23.4 million for the fourth quarter of 2021, and $108.5 million for the year ended December 31, 2022, compared to $74.0 million for the year ended December 31, 2021.
  • Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2022, were $268.1 million, compared to $351.4 million as of December 31, 2021.

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 16, 2023
Cancer, Research, Conference, Autoimmunity, University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cyclophosphamide, Partnership, CAR, SLE, Maintenance, University of Pennsylvania, Lancet, Patient, Autoimmune disease, MG, Autoantibody, Investment, CD19, FDA, Disease, Nature Biotechnology, Immunoglobulin therapy, Clinical trial, Immune system, Investigational New Drug, MuSK protein, Coronavirus Scientific Advisory Board, Food, Drug discovery, IND, Syndrome, Recurrence, Pharmaceutical industry, Cryptocurrency, Cabaletta

PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • We believe the tolerability data reported by IASO in these patients support clinical development in patients with autoimmune diseases.
  • These data were developed through a sponsored research agreement between Cabaletta Bio and University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta Bio co-founder and Scientific Advisory Board co-chair.
  • As of December 31, 2022, Cabaletta had cash, cash equivalents and investments of $106.5 million, compared to $122.2 million as of December 31, 2021.
  • The Company expects that its cash, cash equivalents and investments as of December 31, 2022, will enable it to fund its operating plan into the first quarter of 2025.

Mammalian Polyclonal IgG Antibody Global Market Report 2023: Growing Prevalence of Standard Laboratory Tests Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, Science, Health, Research, Neoplasm, Syphilis, Prevalence, Antibody, Immunoelectrophoresis, Organization, Epitope, Immunoglobulin G, Conditional sentence, University, Human, COVID-19, IHC, AIDS, Flow cytometry, Immunohistochemistry, Cancer, Hospital, CVD, Government, Anemia, Growth, GSK plc, Viral, Government agency, Acceleration, ELISA, Lyme disease, Mouse, Plasma, Application, Biomarker, Agilent Technologies, USD, Region, Diagnosis, CDC, Western blot, Rabbit, Serum, Autoimmunity, SARS-CoV-2, State, Investment, GenScript Biotech, Animal, Disease, Chip, Incidence, Diabetes, Fine chemical, Pharmaceutical industry, Vaccine, Immunoprecipitation

The "Mammalian Polyclonal IgG Antibody Market by Type, by Product, by Application, by End-user, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mammalian Polyclonal IgG Antibody Market by Type, by Product, by Application, by End-user, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • The mammalian polyclonal IgG antibody market size is estimated to be USD 1,347.4 million in 2022 and is expected to witness a CAGR of 5.28% during the forecast period 2023-2033.
  • Furthermore, growing prevalence of standard laboratory tests, government investment, acceleration in institutional and academic research, and affordability of supporting equipment and technology are other factors supporting the market growth.
  • Growing prevalence of standard laboratory tests such as microarray assays, western blot analysis, immunohistochemical, and cell imaging is predicted to propel the mammalian polyclonal IgG antibody market growth during the forecast period.

Immunocore to present four posters at AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Cancer, American Association for Cancer Research, Infection, Autoimmunity, TCR, Vaccine

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.

Key Points: 
  • (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • & ROCKVILLE, Md., US, 14 March 2023) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, will present four posters at the American Association for Cancer Research Annual Meeting 2023 commencing on 14 April 2023.